The Covid-19, Epidemiology, Clinic and Prevention.
作者信息
Antonelli Alessandro, Elia Giusy, Ferrari Silvia Martina, Foddis Rudy, De Marco Salvatore, Cristaudo Alfonso, Fallahi Poupak
机构信息
1Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; 2Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy; 3U.O. 5 Medicine, AOUP, Pisa, Italy.
出版信息
Curr Genomics. 2020 Apr;21(3):157. doi: 10.2174/1389202921999200427133052.
Abstract
摘要
相似文献
1
The Covid-19, Epidemiology, Clinic and Prevention.
Curr Genomics. 2020 Apr;21(3):157. doi: 10.2174/1389202921999200427133052.
引用本文的文献
1
Thyroid Autoimmunity and SARS-CoV-2 Infection.
J Clin Med. 2023 Oct 5;12(19):6365. doi: 10.3390/jcm12196365.
2
An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.
Int Immunopharmacol. 2021 Jul;96:107763. doi: 10.1016/j.intimp.2021.107763. Epub 2021 May 6.
3
COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series.
Clin Rheumatol. 2020 Nov;39(11):3195-3204. doi: 10.1007/s10067-020-05334-7. Epub 2020 Aug 27.
本文引用的文献
1
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
2
Current Drugs with Potential for Treatment of COVID-19: A Literature Review.
J Pharm Pharm Sci. 2020;23(1):58-64. doi: 10.18433/jpps31002.
3
Insight into 2019 novel coronavirus - An updated interim review and lessons from SARS-CoV and MERS-CoV.
Int J Infect Dis. 2020 May;94:119-124. doi: 10.1016/j.ijid.2020.03.071. Epub 2020 Apr 1.
4
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.
Med Mal Infect. 2020 Jun;50(4):384. doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.
5
The versatile heparin in COVID-19.
J Thromb Haemost. 2020 May;18(5):1020-1022. doi: 10.1111/jth.14821. Epub 2020 Apr 27.
6
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.
Int J Antimicrob Agents. 2020 May;55(5):105954. doi: 10.1016/j.ijantimicag.2020.105954. Epub 2020 Mar 29.
7
Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus.
Ann Palliat Med. 2020 Mar;9(2):428-436. doi: 10.21037/apm.2020.03.26. Epub 2020 Mar 17.
8
Emerging prophylaxis strategies against COVID-19.
Monaldi Arch Chest Dis. 2020 Mar 30;90(1). doi: 10.4081/monaldi.2020.1289.
9
Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients.
Emerg Microbes Infect. 2020 Dec;9(1):761-770. doi: 10.1080/22221751.2020.1747363.
10
COVID-19 and diabetes: Can DPP4 inhibition play a role?
Diabetes Res Clin Pract. 2020 Apr;162:108125. doi: 10.1016/j.diabres.2020.108125. Epub 2020 Mar 26.
Zotero 插件